Angeles Wealth Management LLC cut its position in shares of Stryker Co. (NYSE:SYK – Free Report) by 4.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,245 shares of the medical technology company’s stock after selling 60 shares during the period. Angeles Wealth Management LLC’s holdings in Stryker were worth $448,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in SYK. Ritholtz Wealth Management increased its position in Stryker by 6.3% in the third quarter. Ritholtz Wealth Management now owns 5,140 shares of the medical technology company’s stock worth $1,857,000 after purchasing an additional 306 shares during the last quarter. Retirement Planning Group LLC purchased a new position in shares of Stryker in the 3rd quarter worth $249,000. Exchange Traded Concepts LLC increased its holdings in shares of Stryker by 1.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 5,261 shares of the medical technology company’s stock worth $1,901,000 after buying an additional 96 shares during the last quarter. Koshinski Asset Management Inc. raised its position in shares of Stryker by 4.0% during the 3rd quarter. Koshinski Asset Management Inc. now owns 2,403 shares of the medical technology company’s stock valued at $868,000 after buying an additional 92 shares in the last quarter. Finally, McGlone Suttner Wealth Management Inc. bought a new position in shares of Stryker in the 3rd quarter valued at about $295,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have weighed in on SYK shares. Evercore ISI boosted their price objective on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Royal Bank of Canada increased their price target on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Barclays lifted their price objective on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research note on Monday. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $420.00 price target (up from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $420.68.
Stryker Stock Up 0.2 %
Shares of NYSE:SYK opened at $392.15 on Tuesday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $377.23 and its 200 day moving average is $365.14. The stock has a market cap of $149.49 billion, a P/E ratio of 50.53, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19.
Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the company earned $3.46 EPS. Sell-side analysts predict that Stryker Co. will post 13.49 EPS for the current year.
Stryker Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. Stryker’s payout ratio is presently 43.30%.
Insider Activity
In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.90% of the company’s stock.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Featured Stories
- Five stocks we like better than Stryker
- Learn Technical Analysis Skills to Master the Stock Market
- Merck: 4 No-Brainer Reasons to Buy This Dip
- How to Use the MarketBeat Stock Screener
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- Why is the Ex-Dividend Date Significant to Investors?
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.